🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An #amyloidosis diagnosis impacts the entire family. Mike, who is currently living with AL amyloidosis, discusses his wife’s role as a caregiver for him, and the unwavering support that she has offered throughout his experience with this #raredisease. #AmyloidosisAwarenessMonth

At Prothena, we believe it’s important to elevate firsthand perspectives from patients. Watch as Linda, living with #amyloidosis, offers advice for others who are managing this disease: bit.ly/4cvmpyS #AmyloidosisAwarenessMonth

An #amyloidosis diagnosis can leave patients & families with unanswered questions. We encourage you to check out Amyloidosis Research Consortium’s patient resources to learn more about this condition & the support available to those impacted: arci.org/patient-resour… #AmyloidosisAwarenessMonth

Today's unanimous and positive FDA Peripheral and Central Nervous System Drugs Ad Comm vote marks a step forward in progress for patients, families, and caregivers in treating #Alzheimers disease.

It was great speaking with Healio Neurology about the latest updates from our pipeline and what’s next for Prothena Corporation in the year ahead. We look forward to sharing more about our progress and future initiatives soon. #Alzheimer’s disease; AL #amyloidosis

Collaborative partnerships are fundamental in driving innovation. Check out our discussion with PharmaVoice on our transformative R&D efforts in partnership with Bristol Myers Squibb, aimed at advancing treatments for CNS disorders: bit.ly/3zlE0Ke

A truly significant day for the #Alzheimers community, which further reinforces the disease-modifying ability of Aβ targeting therapies. We at Prothena Corporation will continue to innovate and work with urgency to develop treatments with the patient experience top of mind.

This year, we proudly joined Amyloidosis's Virtual Run/Walk/Roll/Bike Event, spreading awareness in support of #amyloidosis within our local communities. Across the US and EU, our teams came together to participate in this impactful event! #RunForAmyloidosis

AL #amyloidosis can be challenging to diagnose due to its varied symptoms. Hear from those impacted by this #raredisease and the challenges they faced in putting the puzzle pieces together: bit.ly/471coHi

#Alzheimers research is making incredible strides. This article in Forbes discusses the development of next-generation vaccines, including our work at Prothena Corporation, with the potential to offer new hope for patients and their families. Read more: bit.ly/3Xj5cTD

BU and BMC’s Vaishali Sanchorawala, MD, is leading a new study along with the Dana-Farber Cancer Institute for people with advanced stages of AL amyloidosis in Boston. To read more from the Boston Globe, click here: bit.ly/3Ymg8QK

This #WorldAmyloidosisDay, we stand with patients, families, and all others affected by this #raredisease. At Prothena, we remain deeply committed to advancing treatment options and making a difference for the #amyloidosis community.

Join us for our Friday Satellite Symposium, preceding #ASH24. We are proud to sponsor the independent Medscape CME Symposium, “Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis,” tomorrow at 11:30am PT.

#DYK NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend primary treatment for AL #amyloidosis is in a clinical trial? Visit our booth (2027) at #ASH24 to learn more about the AFFIRM-AL clinical trial in Mayo Stage IV AL amyloidosis.

As 2024 comes to a close, we reflect on a remarkable year at Prothena. We want to extend our warmest wishes for a happy and prosperous New Year to our Prothena family, partners in advocacy, and the patients and caregivers we serve. #HappyHolidays

As we enter 2025, our CEO Gene Kinney, highlights our ongoing commitment to supporting the millions affected by neurodegenerative & rare peripheral amyloid diseases. Here’s to a year of continued progress, collaboration, & meaningful impact for the patients & their loved ones.

Participation in the AFFIRM-AL study will help us understand whether an investigational medication is effective for adults newly diagnosed with advanced AL #amyloidosis. Learn more about participating: bit.ly/4cXd2YA

In a conversation with President and CEO, Gene Kinney, we reflect on 2024, discuss what lies ahead for Prothena in 2025 and our ongoing commitment to developing therapies for patients affected by protein dysregulation. Learn more: bit.ly/41L4QqW

We’re excited to share our latest updates as we continue advancing therapies for patients affected by diseases caused by protein dysregulation. 2025 will be a transformational year for Prothena Corporation, with meaningful progress across our R&D portfolio. #amyloidosis #alzheimers

Chad Swanson, Chief Development Officer, joined the “Improving the Therapeutic Potential of Immunotherapies in AD” session at #ADPD2025, where experts came together to discuss the latest research and strategies in slowing disease progression. We stand alongside the